Enhanced fetal hemoglobin production via dual-beneficial mutation editing of the HBG promoter in hematopoietic stem and progenitor cells for β-hemoglobinopathies
Abstract Background Sickle cell disease (SCD) and β-thalassemia patients with elevated gamma globin (HBG1/G2) levels exhibit mild or no symptoms. To recapitulate this natural phenomenon, the most coveted gene therapy approach is to edit the regulatory sequences of HBG1/G2 to reactivate them. By edit...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-12-01
|
Series: | Stem Cell Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13287-024-04117-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|